A scathing report from the House of Lords Science and Technology Committee has warned that the UK's science sector is 'bleeding out' due to persistent funding gaps and uncertainties surrounding post-Brexit research schemes. The report, published on Tuesday, paints a grim picture of a research ecosystem struggling to retain talent, secure long-term investments, and maintain its competitive edge on the global stage.
Baroness Brown of Cambridge, chair of the committee, stated: 'The UK science base is a national treasure, but it is being systematically undermined by short-term thinking and chronic underfunding. We are bleeding out talent and losing out on transformative research opportunities.' The committee's inquiry found that the UK government's pledge to increase R&D spending to 2.4% of GDP by 2027 appears increasingly unrealistic, with current investment stagnating at around 1.7%.
A critical issue highlighted is the delay in finalizing the UK's association to Horizon Europe, the EU's flagship research program. After Brexit, the UK committed to paying for access, but negotiations have stalled, leaving researchers in limbo. 'Every month of delay means lost collaborations, missed grant opportunities, and a brain drain to countries like Germany and Switzerland,' said Professor Sir John Skehel, a fellow of the Royal Society.
The report also criticizes the 'inequitable distribution' of funding across regions. While Oxford and Cambridge thrive, other universities face severe budget cuts. 'We have a two-tier system emerging,' noted Dr. Eleanor Crane, a research policy expert at the University of Manchester. 'The government's focus on a few elite institutions is starving the broader ecosystem.'
Evidence submitted to the committee shows that early-career researchers are particularly affected. Fixed-term contracts and precarious funding streams are driving many to leave academia or move abroad. 'I've had to turn down PhD students because I can't guarantee their stipend,' said Dr. Adam Khan, a materials scientist at the University of Birmingham. 'That's a loss of future innovators.'
In response, a government spokesperson said: 'We are committed to making the UK a science superpower. We are investing an additional £20 billion in R&D by 2024-25 and are working to finalize Horizon Europe association. The UK's success in vaccine development proves our capabilities.' However, the committee dismissed these claims as 'inadequate' given the scale of the challenge.
The report recommends immediate action: a transparent timetable for Horizon Europe association, a 'R&D Fiscal Incentives Review' to boost private investment, and a new 'Research Resilience Fund' to stabilize institutions. Without these measures, the committee warns, the UK risks irreversible damage to its scientific standing.
As global competitors like China and the US ramp up investment, the UK's window for action is narrowing. The choice, the report concludes, is stark: reinvest boldly or watch a once-thriving sector bleed out.








